Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

"This is a very clear effort to shine a light on this anti-vaccine trope: that thimerosal is somehow dangerous.” ...

The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Alberta's decision to reduce access to publicly funded COVID-19 vaccines so far appears to set the province on a different ...

Today, a new ESC Clinical Consensus Statement published in the European Heart Journal discusses the key role of vaccination ...